203 related articles for article (PubMed ID: 23653391)
41. Role of Survivin and p53 Expression in Response of Primary Culture of Ovarian Cancer Cells to Treatment With Chemotherapeutic Agents.
Chawla D; Kar R; Gupta B; Halder S; Garg S; Mehndiratta M; Wadhwa N; Agarwal R
Int J Gynecol Cancer; 2018 Jul; 28(6):1239-1246. PubMed ID: 29727353
[TBL] [Abstract][Full Text] [Related]
42. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
Gotlieb WH; Saumet J; Beauchamp MC; Gu J; Lau S; Pollak MN; Bruchim I
Gynecol Oncol; 2008 Aug; 110(2):246-50. PubMed ID: 18495226
[TBL] [Abstract][Full Text] [Related]
43. [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro].
Zhang SL; Jiang T; Lin B; Zhao CQ; Meng LR
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):482-5. PubMed ID: 15347474
[TBL] [Abstract][Full Text] [Related]
44. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Grènman S
Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
[TBL] [Abstract][Full Text] [Related]
45. Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer.
Singh PP; Joshi S; Russell PJ; Nair S; Khatri A
BMC Cancer; 2011 Aug; 11():368. PubMed ID: 21861932
[TBL] [Abstract][Full Text] [Related]
46. FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Kreitzburg KM; Fehling SC; Landen CN; Gamblin TL; Vance RB; Arend RC; Katre AA; Oliver PG; van Waardenburg RCAM; Alvarez RD; Yoon KJ
Cancer Lett; 2018 Nov; 436():75-86. PubMed ID: 30120964
[TBL] [Abstract][Full Text] [Related]
47. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
[TBL] [Abstract][Full Text] [Related]
48. Metformin and ovarian cancer survival: is there a rational warrant for belief?
Mormile R
Arch Gynecol Obstet; 2019 Oct; 300(4):797-798. PubMed ID: 31346700
[TBL] [Abstract][Full Text] [Related]
49. [Cytokinetic effects of carboplatin and cisplatin on a human ovarian cancer cell line].
Yoshizumi N; Fujiwara J; Yoshizaki A; Sato M; Sakai R; Nishiya I
Hum Cell; 1988 Sep; 1(3):301-7. PubMed ID: 2979207
[TBL] [Abstract][Full Text] [Related]
50. S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro.
Wang Q; He Z; Gao J; Hu S; Huang M; Liu M; Zheng J; Tang H
Cancer Lett; 2008 Dec; 272(2):277-84. PubMed ID: 18762368
[TBL] [Abstract][Full Text] [Related]
51. Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin.
Tzeng TJ; Cao L; Fu Y; Zeng H; Cheng WH
PLoS One; 2014; 9(7):e101664. PubMed ID: 25010594
[TBL] [Abstract][Full Text] [Related]
52. Carboplatin and sodium butyrate, separate--yes, but combined--never.
Gurtowska N; Kloskowski T; Olkowska J; Bajek A; Debski R; Zielaskowska J; Drewa T
Acta Pol Pharm; 2013; 70(1):153-61. PubMed ID: 23610971
[TBL] [Abstract][Full Text] [Related]
53. Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
Tseng SC; Huang YC; Chen HJ; Chiu HC; Huang YJ; Wo TY; Weng SH; Lin YW
Biochem Pharmacol; 2013 Feb; 85(4):583-94. PubMed ID: 23228696
[TBL] [Abstract][Full Text] [Related]
54. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
55. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
56. Autophagy and protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2α) pathway protect ovarian cancer cells from metformin-induced apoptosis.
Moon HS; Kim B; Gwak H; Suh DH; Song YS
Mol Carcinog; 2016 Apr; 55(4):346-56. PubMed ID: 25663310
[TBL] [Abstract][Full Text] [Related]
57. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
58. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
Hanna RK; Zhou C; Malloy KM; Sun L; Zhong Y; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2012 May; 125(2):458-69. PubMed ID: 22252099
[TBL] [Abstract][Full Text] [Related]
59. Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway.
Fu YL; Zhang QH; Wang XW; He H
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(5):1169-1175. PubMed ID: 28338172
[TBL] [Abstract][Full Text] [Related]
60. Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells.
Bishnu A; Sakpal A; Ghosh N; Choudhury P; Chaudhury K; Ray P
Int J Biochem Cell Biol; 2019 Feb; 107():116-127. PubMed ID: 30593952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
